In CKD, empagliflozin reduced kidney disease progression at a median 2 y, regardless of primary kidney disease type

Jin Ho Hwang; Chi-Yuan Hsu

doi:10.7326/J24-0020

In CKD, empagliflozin reduced kidney disease progression at a median 2 y, regardless of primary kidney disease type

Ann Intern Med. 2024 Apr;177(4):JC40. doi: 10.7326/J24-0020. Epub 2024 Apr 2.

Authors

Jin Ho Hwang¹, Chi-Yuan Hsu²

Affiliations

¹ Chung-Ang University College of Medicine, Seoul, South Korea, and University of California, San Francisco, California, USA (J.H.H.).
² University of California, San Francisco, California, USA (C.H.).

PMID: 38560913
DOI: 10.7326/J24-0020

Abstract

EMPA-KIDNEY Collaborative Group. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial. Lancet Diabetes Endocrinol. 2024;12:51-60. 38061372.

MeSH terms

Benzhydryl Compounds*
Cardiovascular Diseases* / complications
Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Disease Progression
Glucosides*
Humans
Kidney
Renal Insufficiency, Chronic* / complications
Renal Insufficiency, Chronic* / drug therapy

Substances

empagliflozin
Benzhydryl Compounds
Glucosides